Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patients
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Fluticasone furoate/umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Comparative efficacy of triple therapies
- 02 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2020 New trial record